Skip to content
Gold Mining News – Lifestyle
Author:
Opus Genetics, Inc.
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
October 16, 2026
Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
October 15, 2026
Opus Genetics to Present at the Chardan Annual Healthcare Conference
October 13, 2026
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027
September 9, 2026
Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences
September 2, 2026
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 19, 2026
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
August 6, 2026
Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease
August 3, 2026
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
July 9, 2026
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
July 6, 2026
1
2
3
Next Page
→